214 related articles for article (PubMed ID: 12271501)
1. [New data prove therapeutic superiority. MabThera in follicular and mantle cell lymphoma].
Krankenpfl J; 2002; 40(5-6):161. PubMed ID: 12271501
[No Abstract] [Full Text] [Related]
2. [Maintenance therapy with rituximab].
Krankenpfl J; 2005; 43(7-10):222-4. PubMed ID: 16515293
[No Abstract] [Full Text] [Related]
3. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
[TBL] [Abstract][Full Text] [Related]
4. [Recent progress in the therapeutic strategy for follicular lymphoma and mantle cell lymphoma].
Ogura M
Rinsho Ketsueki; 2006 Jun; 47(6):495-512. PubMed ID: 16862978
[No Abstract] [Full Text] [Related]
5. Factors predictive for response of follicular and mantle-cell lymphoma to rituximab.
Pfreundschuh M
Nat Clin Pract Oncol; 2006 Apr; 3(4):184-5. PubMed ID: 16596141
[No Abstract] [Full Text] [Related]
6. [Antibody therapy in hematology and oncology - part 1].
Kneba M; Schrader C; Köhne H
Med Klin (Munich); 2008 Dec; 103(12):843-59. PubMed ID: 19099214
[No Abstract] [Full Text] [Related]
7. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
8. [Non-Hodgkin lymphoma becomes curable].
Krankenpfl J; 2005; 43(1-3):40-1. PubMed ID: 15912832
[No Abstract] [Full Text] [Related]
9. Treatment of mantle cell lymphoma: targeting the microenvironment.
Drach J; Seidl S; Kaufmann H
Expert Rev Anticancer Ther; 2005 Jun; 5(3):477-85. PubMed ID: 16001955
[TBL] [Abstract][Full Text] [Related]
10. [Milestone in healing fatal indolent lymphoma].
Krankenpfl J; 2004; 42(3-4):106-7. PubMed ID: 15311904
[No Abstract] [Full Text] [Related]
11. Rituxan: the new kid on the block.
Jonas C
Oncol Nurs Forum; 1998 May; 25(4):669. PubMed ID: 9599347
[No Abstract] [Full Text] [Related]
12. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma.
Bauwens D; Maerevoet M; Michaux L; Théate I; Hagemeijer A; Stul M; Danse E; Costantini S; Vannuffel P; Straetmans N; Vekemans MC; Deneys V; Ferrant A; Van Den Neste E
Br J Haematol; 2005 Nov; 131(3):338-40. PubMed ID: 16225653
[TBL] [Abstract][Full Text] [Related]
13. Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
Cheson BD
Clin Adv Hematol Oncol; 2008 Sep; 6(9):4-6. PubMed ID: 18998258
[No Abstract] [Full Text] [Related]
14. Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study.
Van Oers MH; Hagenbeek A; Van Glabbeke M; Teodorovic I
Ann Hematol; 2002 Oct; 81(10):553-7. PubMed ID: 12424535
[No Abstract] [Full Text] [Related]
15. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
16. [II. Treatment trend and outlook on bendamustine for mantle cell lymphoma and follicular lymphoma].
Ogura M
Gan To Kagaku Ryoho; 2012 May; 39(5):736-42. PubMed ID: 22701900
[No Abstract] [Full Text] [Related]
17. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
18. A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.
O'Connor OA; Portlock C; Moskowitz C; Straus D; Hamlin P; Stubblefield M; Dumetrescu O; Colevas AD; Grant B; Zelenetz A
Br J Haematol; 2008 Oct; 143(2):201-9. PubMed ID: 18691173
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
20. New therapies for mantle cell lyphoma.
Williams ME
Clin Adv Hematol Oncol; 2003 Dec; 1(12):708, 11. PubMed ID: 16258472
[No Abstract] [Full Text] [Related]
[Next] [New Search]
